Perhaps the biggest supply issue for cell and gene therapies is a lack of reliable sources of GMP-grade plasmid DNA. The supply of pDNA – and, therefore, mRNA – is constrained by both manufacturing issues and short supply of consumables […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.
SEO plus – Test
- 20+ years at GSK, leading R&D activities on multiple vaccine programs
- Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
- Key areas of expertise are:
- Process development of protein Biologics/Recombinant Antigens
- Recombinant protein expression (mammalian, insect, yeast, bacterial)
- Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
- Protein Engineering and Structural Biology
- Defining quality attributes, biophysical characterization of proteins, and analytical strategy
- Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
- 25+ Patent & 5 Scientific Publications
Normand Blais – Senior Director Development & Innovation, Biologics
- 20+ years at GSK, leading R&D activities on multiple vaccine programs
- Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
- Key areas of expertise are:
- Process development of protein Biologics/Recombinant Antigens
- Recombinant protein expression (mammalian, insect, yeast, bacterial)
- Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
- Protein Engineering and Structural Biology
- Defining quality attributes, biophysical characterization of proteins, and analytical strategy
- Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
- 25+ Patent & 5 Scientific Publications
Oliver Technow - Chief Executive Officer
- Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
- More than 20 years of global pharmaceutical industry experience.
- Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
- In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ; in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
- Appointed President of BIOVECTRA Inc., December 10, 2015.
- Board Director for BIOTECanada
- Member of the Steering Council of Innovative Medicines Canada (IMC)
- In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
- In November 2019, promoted to Chief Executive Officer at BIOVECTRA
- In June 2020, named new Chair of PEI BioAlliance Board of Directors